Navigation Links
OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial
Date:3/14/2012

SAN DIEGO, March 14, 2012 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB:ONCS), which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that John Wayne Cancer Institute in Santa Monica, CA, and Lakeland Comprehensive Cancer Center in Lakeland, FL have been initiated as enrolling sites, and investigators are screening patients for the Phase II metastatic melanoma clinical trial (OMS-I100).

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

"We are very pleased to have two respected investigators in melanoma clinical research, Drs. Mark Faries and Manuel Molina joining our Phase II clinical study," said Punit Dhillon, President and CEO. "Both the John Wayne Cancer Institute and Lakeland Comprehensive Cancer Center are state of the art clinical sites and represent important centers of excellence that will add value to enrollment targets and expertise by participating in the study."

Dr. Faries, principal investigator at John Wayne Cancer Institute said, "We are enthusiastic about OncoSec's OMS ElectroImmunotherapy treatment approach for cutaneous, in-transit metastatic melanoma. The treatment is easy to administer and has the potential to provide patients an alternative therapy for this deadly disease."

Dr. Molina, principal investigator at Lakeland Comprehensive Cancer Center said, "Data from the Phase I study was very impressive, which demonstrated that the therapy was not only safe but also provided durable therapeutic benefit. Advancing into a Phase II study is encouraging and is important for validation of results seen in the Phase I study.  We look forward to participating in this trial."

Along with these sites and the University of California San Francisco, the company plans to initiate several additional centers of
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. OncoSec to Evaluate Potential Predictive or Prognostic Biomarkers for Treatment of Solid Tumor Cancers Using OMS ElectroImmunotherapy
2. OncoSecs OMS ElectroImmunotherapy Technology Platform and its Ongoing Phase II Merkel Cell Carcinoma Clinical Trial Featured in Seattle Newspaper
3. OncoSec Doses First Patient in Phase II Clinical Trial for Metastatic Melanoma
4. OncoSec to Present at World Cancer Immunotherapy Conference
5. OncoSec to Present at the 22nd Annual Oppenheimer Healthcare Conference
6. OncoSec to Present at 15th Annual Biotech and Specialty Pharmaceuticals Conference
7. OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies
8. OncoSec to Present at Medical Device Investor Forum
9. Device Master File for OncoSec Medical System Completed and Submitted to FDA
10. OncoSec Releases Devices for Use in Clinical Trials
11. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 A decade-long ... in Helmholtz Zentrum München, Germany , ... autoantibodies and the risk of developing type 1 diabetes ... preventions for the disease. The study, "Seroconversion to Multiple ... Children," was published today in The Journal of ...
(Date:6/19/2013)... , June 19, 2013   Voices Against ... finding a cure for brain cancer, today announced that ... grant to support the clinical investigation of Toca 511 ... high grade glioma brain cancer (Grade 3 or Grade ... novel treatments for advanced cancer, with an initial focus ...
(Date:6/19/2013)... N.Y. , June 19, 2013 ... sourcing company servicing all branches of government from ... they have expanded their facilities to include complex ... designed and fabricated some very complex aluminum parts ... continue to expand our capabilities to service government ...
Breaking Medicine Technology:New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 2New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 3Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Amerivet Solutions Expands to Manufacture Complex Metal Designs 2
... 2011 Cebix Incorporated announced today it ... for the treatment of complications of diabetes. The biopharmaceutical ... evaluate Ersatta™, its proprietary long-acting form of C-peptide, in ... disease, lack this endogenous peptide.  Following the successful completion ...
... GREENWOOD VILLAGE, Colo., June 16, 2011 Ampio Pharmaceuticals, ... discovers and develops new uses for previously approved drugs ... is set to join the U.S. broad-market Russell 3000 ... U.S. and global equity indices on June 24, according ...
Cached Medicine Technology:Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 2Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 3Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™ 4Ampio Pharmaceuticals Set to Join Russell 3000 Index 2Ampio Pharmaceuticals Set to Join Russell 3000 Index 3
(Date:6/19/2013)... June 19 online edition of the journal Nature ... University of California, San Diego School of Medicine visually ... cardiac regeneration occurs in zebrafish after cardiac ventricular injury. ... in the heart are more plastic, or capable of ... More importantly, the research reveals a novel potential source ...
(Date:6/19/2013)... understanding of the genetic process that can lead to ... lesions for some women, and also raises a warning ... cases suggesting they could actually trigger the cancer ... a clearer picture of the chromosomal and genetic changes ... to chronic infection and, in less than 1 percent ...
(Date:6/19/2013)... significant disparities between minority and white clients in ... Moreover, these disparities vary widely from state to ... most states there,s something amiss," says Stephan Arndt, ... are strong racial and ethnic disparities for people ... programs successfully, and those disparities are something we ...
(Date:6/19/2013)... In early April, senior leaders from medical, law ... to discuss one question: how can first responders improve ... The preliminary results of this discussion are now available ... Hartford Consensus ," a concept paper published in the ... Trauma and Acute Care Surgery , official publication ...
(Date:6/19/2013)... Nearly 70 percent of Americans are on at ... take two, Mayo Clinic researchers say. Antibiotics, antidepressants ... study found. Twenty percent of patients are on ... findings, published online in the journal Mayo ... and video of Dr. Jennifer St. Sauver talking ...
Breaking Medicine News(10 mins):Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2Health News:Genetics of cervical cancer raise concern about antiviral therapy in some cases 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Hartford consensus aims to improve survival after mass shootings 2Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2
... science and progress of integrative medicine in the ... convene the "Summit on Integrative Medicine and the ... D.C. The summit will bring together distinguished researchers, ... the vision, challenges, evidence base, and opportunities for ...
... Control Weight Permanently , MIDLAND, Mich., Jan. 27 ... is the challenge. With this Health Enhancement Systems ... Healthy Weight for Life ( ... gain control of their weight -- and improve their health ...
... the fight against,oral cancer is now being offered by Barotz ... http://www.barotzdental.com , determines a,person,s risk for oral cancer disease in ... Americans are diagnosed with oral cancer each year. While,easy ... death rate,because it is routinely discovered late in its development," ...
... of the European Heart Rhythm Association (EHRA), is today ... More than 4,000 participants are expected to attend this ... and sudden cardiac death. , EHRA is a registered ... mission is to reduce the impact of cardiac arrhythmias ...
... Meanwhile, U.S. officials say illnesses linked to tainted peanut ... 27 (HealthDay News) -- The Georgia facility that produced ... nationwide salmonella outbreak has a history of health-inspection violations, ... officials reported Monday that the outbreak, which has now ...
... Forever" Solution , , DALLAS, Jan. 27 ... it,s swept under the rug as a nuisance. However, ... an indicator of a serious health problem called obstructive sleep ... of Plano is announcing a dental approach to end snoring ...
Cached Medicine News:Health News:IOM gathers health care leaders for summit on integrative medicine 2Health News:Thousands Look Better, Feel Better, and Have More Energy Because of NutriSum 2Health News:Barotz Dental Offers Free Online Oral Cancer Risk Assessment 2Health News:EUROPACE 2009 2Health News:Salmonella Outbreak Site Has History of Health Violations: Report 2Health News:Spouses of the Lone Star State Rejoice As Snoring Is DOA 2
For determination of triglycerides in serum or plasma. For Hitachi 704 / 911. Available with calibrator: Trucal U and also with controls: Trulab N, Trulab P, Trulab L....
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 1000 mg/dL (11.3 mmol/L). Single vial, dry powder reagent....
For the quantitative determination of triglycerides in serum. Linearity: 1000 mg/dl....
Alkaline phosphatase FS (IFCC). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Medicine Products: